AVXL posts a Q2 GAAP EPS of -$0.06 as cash reserves rise to $127.4 million, extending funding runway into late 2028.
Anavex Life Sciences reported a GAAP loss of $0.06 per share for the second quarter, matching preliminary figures. The company’s cash and cash equivalents reached $127.4 million as of March 31, 2026, up from $102.6 million at the end of September 2025.
The increase in cash reserves reflects operational adjustments and funding strategies. Anavex expects the current balance to sustain operations into mid-to-late fiscal 2028, providing a longer runway for clinical and development initiatives.
No immediate market reaction was disclosed in the release.